Penumbra (NYSE:PEN) posted its quarterly earnings data on Tuesday, May 7th. The company reported $0.23 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.10, Morningstar.com reports. The company had revenue of $128.44 million for the quarter, compared to analyst estimates of $123.09 million. Penumbra had a net margin of 2.51% and a return on equity of 5.84%. Penumbra’s quarterly revenue was up 25.1% on a year-over-year basis. During the same period in the previous year, the business posted $0.15 earnings per share.
PEN traded down $3.60 during trading on Friday, hitting $142.70. 346,869 shares of the company’s stock were exchanged, compared to its average volume of 410,556. The company has a quick ratio of 4.34, a current ratio of 6.10 and a debt-to-equity ratio of 0.11. Penumbra has a 1 year low of $110.84 and a 1 year high of $167.35. The company has a market cap of $5.08 billion, a P/E ratio of 279.80, a P/E/G ratio of 7.30 and a beta of 0.71.
In other Penumbra news, CEO Adam Elsesser sold 8,000 shares of the stock in a transaction on Monday, March 11th. The shares were sold at an average price of $139.86, for a total transaction of $1,118,880.00. Following the transaction, the chief executive officer now directly owns 1,115,838 shares in the company, valued at approximately $156,061,102.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Arani Bose sold 55,000 shares of the stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $160.07, for a total transaction of $8,803,850.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 94,175 shares of company stock valued at $14,150,971. 9.60% of the stock is owned by insiders.
PEN has been the topic of a number of research analyst reports. ValuEngine raised shares of Penumbra from a “hold” rating to a “buy” rating in a report on Friday, March 15th. Zacks Investment Research raised shares of Penumbra from a “hold” rating to a “buy” rating and set a $157.00 price target on the stock in a report on Tuesday, March 5th. William Blair assumed coverage on shares of Penumbra in a report on Tuesday, May 21st. They issued an “outperform” rating on the stock. JPMorgan Chase & Co. raised shares of Penumbra from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $140.00 to $170.00 in a research report on Thursday. Finally, HC Wainwright reissued a “buy” rating on shares of Penumbra in a research report on Wednesday, April 17th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $145.86.
TRADEMARK VIOLATION WARNING: “Penumbra (PEN) Posts Quarterly Earnings Results, Beats Expectations By $0.10 EPS” was published by Rockland Register and is the property of of Rockland Register. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://rocklandregister.com/2019/05/31/penumbra-pen-posts-quarterly-earnings-results-beats-expectations-by-0-10-eps.html.
Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands.
See Also: Options Trading – What is a Straddle?
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.